Irazu Oncology is focused on developing a flexible platform for cancer therapeutics, specifically through their innovative vaccine technology. Their proprietary Membrane Vesicle Platform (MVP) utilizes Outer Membrane Vesicles (OMVs) derived from engineered, attenuated bacteria. These OMVs are designed to present tumor antigens on their surface, which are crucial for stimulating the immune system. By leveraging this technology, Irazu aims to create cancer vaccines that are not only faster and more cost-effective but also customizable to target a wide range of solid tumors.

The OMV vaccines developed by Irazu Oncology are characterized by several key features that enhance their effectiveness. They can be quickly designed and produced at a low cost, making them accessible for broader applications. The platform allows for the integration of plug-and-play antigen cassettes, enabling customization for specific tumor types. Additionally, the size of the OMVs is optimized to facilitate uptake by lymph nodes, and they are self-adjuvanted, which means they can enhance the immune response without the need for additional adjuvants. This combination of attributes positions Irazu's technology as a promising advancement in the field of cancer immunotherapy.

United States

Our mission is to develop a superior vaccine platform to improve clinical outcomes for cancer patients.

Irazu Oncology

Company Details